Sesen Bio (NASDAQ:SESN) Shares Up 2.1%

Share on StockTwits

Shares of Sesen Bio Inc (NASDAQ:SESN) shot up 2.1% on Wednesday . The stock traded as high as $0.58 and last traded at $0.59, 22,374 shares were traded during mid-day trading. A decline of 98% from the average session volume of 1,359,874 shares. The stock had previously closed at $0.58.

Several brokerages recently weighed in on SESN. Zacks Investment Research raised shares of Sesen Bio from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised shares of Sesen Bio from a “sell” rating to a “hold” rating in a research note on Thursday, January 16th.

The company has a market cap of $65.68 million, a PE ratio of -0.51 and a beta of 0.99. The firm has a fifty day simple moving average of $0.75 and a 200 day simple moving average of $1.01.

Sesen Bio (NASDAQ:SESN) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.24). Sell-side analysts anticipate that Sesen Bio Inc will post -0.41 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Private Advisor Group LLC grew its holdings in Sesen Bio by 78.9% in the 4th quarter. Private Advisor Group LLC now owns 34,000 shares of the company’s stock valued at $35,000 after buying an additional 15,000 shares during the period. Oxford Asset Management LLP purchased a new stake in Sesen Bio in the 4th quarter valued at about $176,000. Virtu Financial LLC grew its holdings in Sesen Bio by 71.3% in the 4th quarter. Virtu Financial LLC now owns 195,976 shares of the company’s stock valued at $204,000 after buying an additional 81,603 shares during the period. Credit Suisse AG purchased a new stake in Sesen Bio in the 4th quarter valued at about $261,000. Finally, Geode Capital Management LLC grew its holdings in shares of Sesen Bio by 5.4% during the 4th quarter. Geode Capital Management LLC now owns 723,126 shares of the company’s stock worth $752,000 after purchasing an additional 37,081 shares during the period. Institutional investors own 17.24% of the company’s stock.

Sesen Bio Company Profile (NASDAQ:SESN)

Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.

Further Reading: How much can an individual set aside as a catch-up contribution?

Receive News & Ratings for Sesen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sesen Bio and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Patterson Companies  Reaches New 12-Month Low at $12.93
Patterson Companies Reaches New 12-Month Low at $12.93
KAR Auction Services  Reaches New 1-Year Low at $9.47
KAR Auction Services Reaches New 1-Year Low at $9.47
GreenSky  Hits New 12-Month Low at $3.05
GreenSky Hits New 12-Month Low at $3.05
Berenberg Bank Reiterates “€14.50” Price Target for Deutsche EuroShop
Berenberg Bank Reiterates “€14.50” Price Target for Deutsche EuroShop
Delivery Hero  PT Set at €94.00 by UBS Group
Delivery Hero PT Set at €94.00 by UBS Group
Dialog Semiconductor  PT Set at €38.00 by Kepler Capital Markets
Dialog Semiconductor PT Set at €38.00 by Kepler Capital Markets


© 2006-2020 Ticker Report